Risk of hemorrhagic stroke in warfarin-treated patients following heart valve replacement: Findings from the MAGPIE study

Abstract

Hemorrhagic stroke (HS) remains a serious and potentially disabling complication following heart valve replacement (HVR). We aimed to evaluate the incidence and predictors of HS among mechanical HVR patients in Bangladesh. The Multidimensional Approach of Genotype and Phenotype In Stroke Etiology (MAGPIE) is an ambispective study recruited 568 consecutive HVR patients who had long-term (≥6 months) warfarin therapy between January 2010 and December 2024. Among the 568 HVR patients, 4.4% experienced HS, with a mortality rate of 52%, and the median age was 40 years (interquartile range [IQR]: 32–45). The median duration of warfarin uses among mechanical heart valve patients with HS varied by procedure: 63 months (IQR: 48–86) for mitral valve replacement, 60 months (12–85) for aortic valve replacement, 96 months (52–101.50) for double valve replacement, and 42 months (24–60) for patients undergoing coronary artery bypass grafting (CABG) with valve replacement. Additionally, a receiver operating characteristic curve analysis identified 104 months as the discriminatory threshold for warfarin therapy duration in predicting post-HVR HS onset. An age- and sex-adjusted logistic regression model identified severe pulmonary hypertension (odds ratio [OR] 4.44; 95% confidence interval [CI] 1.15–17.04; p = 0.02) and warfarin therapy duration ≥104 months (OR 1.99; 95% CI 1.00–3.76; p = 0.04) as independent predictors of HS in patients with mechanical HVR. Severe pulmonary hypertension was associated with a 4.4-fold higher risk and warfarin therapy beyond 104 months with a twofold higher risk of HS among patients with mechanical HVR.

Keywords

Bangladesh / heart valve replacement / hemorrhagic stroke / mechanical valve / mortality

References

[1] Colli A, Verhoye JP, Leguerrier A, Gherli T. Anticoagulation or antiplatelet therapy of bioprosthetic heart valves recipients: an unresolved issue. Eur J Cardiothorac Surg. 2007; 31(4): 573-577.

[2] Islam KS, Paul AK. Is bridging anticoagulation with heparin after valve replacement surgery mandatory?—A prospective observational study in a centre of Bangladesh. Cardiovasc J. 2020; 13(1): 27-34.

[3] Chowdhury ZS, Shahjin F, Akter F, et al. Effect of VKORC1 and CYP2C9 polymorphisms on warfarin dose requirement in Bangladeshi population. Pak J Pharm Sci. 2017; 30(2): 341-346.

[4] Sridharan K, Al Banna R, Husain A. Therapeutic audit of patients on warfarin in an anticoagulation clinic of a tertiary care hospital. Clin Ter. 2022; 173(6): 579-584.

[5] Sánchez-Medina FF, Valenzuela-Antelo O, Valenzuela-Molina LC, Arias-Martínez J, López-Morales CM, Ornelas-Aguirre JM. Thromboembolic and hemorrhagic complications in patients with prosthetic heart valves cared for in a tertiary care center. What have we learned? Gac Med Mex. 2023; 159(3): 210-218.

[6] Liu Y, Yu XY, Zhong SL, et al. [Clinical application of anticoagulation treatment with warfarin after prosthetic heart valve replacement: a single center-based survey]. Nan Fang Yi Ke Da Xue Xue Bao. 2010; 30(10): 2242-2245. Chinese.

[7] Palareti G, Antonucci E, Migliaccio L, et al. Vitamin K antagonist therapy: changes in the treated populations and in management results in Italian anticoagulation clinics compared with those recorded 20 years ago. Intern Emerg Med. 2017; 12(8): 1109-1119.

[8] Ahmed NO, Osman B, Abdelhai YM, El-Hadiyah TMH. Impact of clinical pharmacist intervention in anticoagulation clinic in Sudan. Int J Clin Pharm. 2017; 39(4): 769-773.

[9] Rosendaal FR, Cannegieter SC, van der Meer FJM, Briët E. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost. 1993; 69(3): 236-239.

[10] Shoeb M, Fang MC. Assessing bleeding risk in patients taking anticoagulants. J Thromb Thrombolysis. 2013; 35(3): 312-319.

[11] Guerrouij M, Uppal CS, Alklabi A, Douketis JD. The clinical impact of bleeding during oral anticoagulant therapy: assessment of morbidity, mortality and post-bleed anticoagulant management. J Thromb Thrombolysis. 2011; 31(4): 419-423.

[12] Veeger NJGM, Piersma-Wichers M, Tijssen JGP, Hillege HL, van der Meer J. Individual time within target range in patients treated with vitamin K antagonists: main determinant of quality of anticoagulation and predictor of clinical outcome. A retrospective study of 2300 consecutive patients with venous thromboembolism. Br J Haematol. 2005; 128(4): 513-519.

[13] Hylek EM, Singer DE. Risk factors for intracranial hemorrhage in outpatients taking warfarin. Ann Intern Med. 1994; 120(11): 897-902.

[14] Chin KM, Channick RN, de Lemos JA, Kim NH, Torres F, Rubin LJ. Hemodynamics and epoprostenol use are associated with thrombocytopenia in pulmonary arterial hypertension. Chest. 2009; 135: 130-136.

[15] Ranjan R, Adhikary D, Saha SK, Mandal S, Hasan K, Adhikary AB. Impact of prosthetic heart valves on pregnancy in Bangladeshi women. Perfusion. 2019; 34(6): 446-452.

[16] Ranjan R, Adhikary D, Adhikary AB. Pregnancy outcome with prosthetic heart valve in Bangladesh: a retrospective cohort study. Mymensingh Med J. 2019; 28(3): 620-626.

[17] Ranjan R, Adhikary D, Barman S, et al. Multidimensional approach of genotype and phenotype in stroke etiology: the MAGPIE study. Health Sci Rep. 2024; 7(12): e70227.

[18] Faqih SA, Noto-Kadou-Kaza B, Abouamrane LM, et al. Pulmonary hypertension: prevalence and risk factors. Int J Cardiol Heart Vasc. 2016; 11: 87-89.

[19] Christersson C, Ståhle E, Lindhagen L, James S. Haemorrhagic stroke and major bleeding after intervention with biological aortic valve prosthesis: risk factors and antithrombotic treatment. Eur Heart J Suppl. 2020; 22: C26-C33.

[20] Nishimura K, Koga M, Minematsu K, et al. Intracerebral hemorrhage in patients after heart valve replacement. J Neurol Sci. 2016; 363: 195-199.

[21] Alwaqfi N, AlBarakat MM, Qariouti H, Ibrahim K, Alzoubi N. Stroke after heart valve surgery: a single center institution report. J Cardiothorac Surg. 2024; 19(1): 518.

[22] Swinkels BM, de Mol BA, Kelder JC, Vermeulen FE, Ten Berg JM. Long-term bleeding events after mechanical aortic valve replacement in patients under the age of 60. Neth Heart J. 2015; 23(2): 111-115.

[23] Eschenbach LK, Erlebach M, Deutsch MA, et al. Stroke after transcatheter aortic valve replacement: a severe complication with low predictability. Catheter Cardiovasc Interv. 2022; 99(6): 1897-1905.

[24] Messé SR, Acker MA, Kasner SE, et al. Stroke after aortic valve surgery: results from a prospective cohort. Circulation. 2014; 129(22): 2253-2261.

[25] Piper C, Hering D, Langer C, Horstkotte D. Etiology of stroke after mechanical heart valve replacement—results from a ten-year prospective study. J Heart Valve Dis. 2008; 17(4): 413-417.

[26] Hou H, Yue A, Hao X, Yang L, Xue Y. Related factors and safety of reaching the therapeutic target of warfarin after heart valve surgery in hospitalized patients: a retrospective cohort study. Exp Ther Med. 2024; 29(2): 40.

[27] Puskas J, Gerdisch M, Nichols D, et al. Reduced anticoagulation after mechanical aortic valve replacement: interim results from the prospective randomized on-X valve anticoagulation clinical trial randomized Food and Drug Administration investigational device exemption trial. J Thorac Cardiovasc Surg. 2014; 147(4): 1202-1210.

[28] Shrestha P, Koirala B, Shrestha N, Thapa P. A study on complication and monitoring of warfarin in post-valve surgery. J Nepal Med Assoc. 2009; 48(174): 111-115.

[29] Wang X, Xu B, Liang H, et al. Distribution characteristics and factors influencing oral warfarin adherence in patients after heart valve replacement. Patient Prefer Adherence. 2018; 12: 1641-1648.

[30] Montazeri N, Pourmehr S, Ziapour A, Moghadam RH. Blood coagulation monitoring of patients with mechanical heart valve visiting Imam. J Cardiothorac Surg. 2025; 20(1): 68.

[31] Louis L, Bair N, Banjac S, Dweik RA, Tonelli AR. Subdural hematomas in pulmonary arterial hypertension patients treated with protacyclin analogs. Pulm Circ. 2012; 2(4): 518-521.

[32] Shah TG, Sutaria JM, Vyas MV. The association between pulmonary hypertension and stroke: a systematic review and meta-analysis. Int J Cardiol. 2019; 295: 21-24.

[33] Roy B, Vacas S, Ehlert L, McCloy K, Saggar R, Kumar R. Brain structural changes in patients with pulmonary arterial hypertension. J Neuroimaging. 2021; 31(3): 524-531.

[34] Malenfant S, Brassard P, Paquette M, et al. Continuous reduction in cerebral oxygenation during endurance exercise in patients with pulmonary arterial hypertension. Physiol Rep. 2020; 8(6): e14389.

[35] Grzymala-Lubanski B, Svensson PJ, Renlund H, Jeppsson A, Själander A. Warfarin treatment quality and prognosis in patients with mechanical heart valve prosthesis. Heart. 2017; 103(3): 198-203.

[36] Björn R, Lehto J, Malmberg M, et al. Antithrombotic medication and major complications after mechanical aortic valve replacement. Am J Cardiol. 2023; 204: 185-194.

[37] Sakusic A, Rabinstein AA, Anisetti B, et al. Timing of anticoagulation resumption and risk of ischemic and hemorrhagic complications in patients with ICH and mechanical heart valves. Neurology. 2024; 103(4): e209664.

[38] Labaf A, Grzymala-Lubanski B, Själander A, Svensson PJ, Stagmo M. Glomerular filtration rate and association to stroke, major bleeding, and death in patients with mechanical heart valve prosthesis. Am Heart J. 2015; 170(3): 559-565.

[39] Mak M, Lam C, Pineda SJ, et al. Pharmacogenetics of warfarin in a diverse patient population. J Cardiovasc Pharmacol Ther. 2019; 24(6): 521-533.

[40] Salem DN, Stein PD, Al-Ahmad A, et al. Antithrombotic therapy in valvular heart disease—native and prosthetic. Chest. 2004; 126(3suppl): 457S-482S.

Rights & permissions

2026 The Author(s). Ibrain published by Affiliated Hospital of Zunyi Medical University (AHZMU) and Wiley-VCH GmbH.